Living with uncertainty: antidepressants and pregnancy

Ian Jones , Liz McDonald
  • Declaration of interest

    I.J. has received honoraria from Lilly, GlaxoSmithKline, Lundbeck, Janssen, and AstraZeneca for giving talks on psychoeducation for bipolar disorder and his research on prenatal psychosis.

Abstract

There have been a large number of studies in recent years reporting on the reproductive safety of antidepressant medication. Some studies, but not all, have reported an association of antidepressant exposure in pregnancy and the subsequent development of autism spectrum disorders. It remains difficult to know whether the modest increase in risk is due to the medication, to the mood disorder itself, or to other confounding factors. For any individual woman the decision to commence or continue antidepressant medication in pregnancy must be made after a full consideration of the potential risks and benefits of all options, including non-pharmacological treatments. In making these difficult decisions it is important to recognise that episodes of severe psychiatric illness may have very serious negative consequences for the woman, her baby and her family, and these must be weighed against what is known about the risks of taking medication.

View Full Text

Log in through your institution

Purchase Short-Term Access 
Pay per Article - You may access this article (and download the PDF version) for 1 day for US$30.00.
Pay per Issue - You may access this issue (from the computer you are currently using) for 365 days for US$90.00.
Pay for Admission - You may access all content in The British Journal of Psychiatry (and download the PDF version) for 1 day for US$45.00.
Regain Access - You can regain access to a recent Pay per Article, Pay per Issue, or Pay for Admission purchase if your access period has not yet expired.